SOURCE-LINKED STUDY SUMMARY
Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance
Abstract summarizedQuality not appraised
- What was studied
- This preprint analyzed an independent public testing dataset to assess purity, measured peptide abundance, and endotoxin contamination in gray-market research peptides, and compared costs with pharmaceutical alternatives.
- Who / model studied
- The dataset contained 6441 samples across fourteen compounds, including BPC-157, cagrilintide, CJC-1295, GHK-Cu, retatrutide, semaglutide, and tirzepatide. These were product samples, not treated patients.
- Studied dose & schedule
- Dose and schedule were not reported in the source used for this summary.
- What the study found
- Using two quality frameworks modeled on compounded-drug and approved-peptide standards, 41.6% to 71.1% of samples failed the applied criteria. Measurable endotoxin was reported in 15%. Gray-market products cost less, but this did not establish safety.
- Limitations & context
- The authors caution that consumer-directed third-party testing captures only a small fraction of the safety profile relevant to people injecting these preparations.
Read summary source ↗ · Prepared 9/24/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.20944/preprints202604.1748.v1